Surveillance of adverse events following the introduction of inactivated poliovirus vaccine made from Sabin strains (sIPV) to the Chinese EPI and a comparison with adverse events following inactivated poliovirus vaccine made from wild strains (wIPV) in Jiangsu, China

References

• Global Polio Eradication Initiative. Polio eradication and endgame strategic plan 2013–2018. Geneva (Switzerland): World Health Organization; 2013 [accessed 2020 Oct 23]. http://polioeradication.org/wp-content/uploads/2016/07/PEESP_EN_A4.pdf.
   Google Scholar
• Garon J, Seib K, Orenstein WA, Ramirez Gonzalez A, Chang Blanc D, Zaffran M, Patel M. Polio endgame: the global switch from tOPV to bOPV. Expert Rev Vaccines. 2016;15(6):693–708. PMID: 26751187. doi:10.1586/14760584.2016.1140041.
   PubMed Web of Science ®Google Scholar
• van den Ent MMVX, Swift RD, Anaokar S, Hegg LA, Eggers R, Cochi SL. Contribution of global polio eradication initiative-funded personnel to the strengthening of routine immunization programs in the 10 focus countries of the polio eradication and endgame strategic plan. J Infect Dis. 2017;216(suppl 1):S244–9. PMID: 28838165. doi:10.1093/infdis/jiw567.
   PubMedGoogle Scholar
• Hampton LM, Farrell M, Ramirez-Gonzalez A, Menning L, Shendale S, Lewis I, Rubin J, Garon J, Harris J, Hyde T, et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine-worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(35):934–38. PMID: 27606675. doi:10.15585/mmwr.mm6535a3.
   PubMed Web of Science ®Google Scholar
• Gurung S, Harris JB, Eltayeb AO, Hampton LM, Diorditsa S, Avagyan T, Schluter WW. Experience with inactivated polio vaccine introduction and the “switch” from trivalent to bivalent oral polio vaccine in the World Health Organization’s Western Pacific region. J Infect Dis. 2017;216(suppl_1):S101–S108. PMID: 28838170. doi:10.1093/infdis/jiw574.
   PubMedGoogle Scholar
• China Ministry of Health. The EPI immunization schedule for children and it’s instructions (2016 Edition). Beijing: China Ministry of Health; 2016 [accessed 2021 Jan 15]. http://www.nhc.gov.cn/jkj/s3581/201701/a91fa2f3f9264cc186e1dee4b1f24084.shtml.
   Google Scholar
• World Health Organization. Polio Vaccines: WHO position paper-March, 2016. Wkly Epidemiol Rec. 2016;91(12):145–68. [accessed 2020 Oct 23]. https://www.who.int/wer/2016/wer9112.pdf?ua=1.
   PubMedGoogle Scholar
• Iqbal S, Shi J, Seib K, Lewis P, Moro PL, Woo EJ, Shimabukuro T, Orenstein WA. Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US vaccine adverse event reporting system, 2000–12. Lancet Infect Dis. 2015;15(10):1175–82. PMID: 26289956. doi:10.1016/S1473-3099(15)00059-6.
   PubMed Web of Science ®Google Scholar
• Schumacher Z, Bourquin C, Heininger U. Surveillance for adverse events following immunization (AEFI) in Switzerland—1991–2001. Vaccine. 2010;28(24):4059–64. PMID: 20406662. doi:10.1016/j.vaccine.2010.04.002.
   PubMed Web of Science ®Google Scholar
• Previsani N, Tangermann RH, Tallis G, Jafari HS. World health organization guidelines for containment of poliovirus following type-specific polio eradication - worldwide, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(33):913–17. PMID: 26313474. doi:10.15585/mmwr.mm6433a5.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Summary report on the meeting of national coordinators for poliovirus containment on the WHO global action plan to minimize poliovirus facility associated risk (GAPIII). Tunis (Tunisia); 2015 [accessed 2020 Oct 23]. https://applications.emro.who.int/docs/IC_Meet_Rep_2015_EN_16434.pdf.
   Google Scholar
• Okayasu H, Sutter RW, Jafari HS, Takane M, Aylward RB. Affordable inactivated poliovirus vaccine: strategies and progress. J Infect Dis. 2014;210(Suppl1):S459–64. PMID: 25316868. doi:10.1093/infdis/jiu128.
   PubMedGoogle Scholar
• Global Polio Eradication Initiative. Call for expressions of interest (EoI)— developing Sabin-inactivated polio vaccine (sIPV). Global Polio Eradication Initiative; 2012 [accessed 2020 Oct 23]. https://www.who.int/immunization/sage/6_Polio_call_for_EOOI.pdf?ua=1.
   Google Scholar
• World Health Organization. Guidelines for the safe production and quality control of poliomyelitis vaccines. WHO Tech Rep Ser. 2019;1016:213. [accessed 2020 Oct 23]. https://www.who.int/biologicals/vaccines/Annex_4_WHO_TRS_1016_web4.pdf.
   Google Scholar
• Shimizu H. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan. Vaccine. 2016;34(16):1975–85. PMID: 25448090. doi:10.1016/j.vaccine.2014.11.015.
   PubMed Web of Science ®Google Scholar
• Sutter RW, Bahl S, Deshpande JM, Verma H, Ahmad M, Venugopal P, Rao JV, Agarkhedkar S, Lalwani SK, Kunwar A, et al. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomized controlled trial. Lancet. 2015;386(10011):2413–21. PMID: 26388534. doi:10.1016/S0140-6736(15)00237-8.
   PubMed Web of Science ®Google Scholar
• He H, Wang Y, Deng X, Yue C, Tang X, Li Y, Liu Y, Yin Z, Zhang G, Chen Z, et al. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial. Lancet Infect Dis. 2020;20(9):1071–79. PMID: 32442523. doi:10.1016/S1473-3099(19)30738-8.
   PubMed Web of Science ®Google Scholar
• Tang R, Li G, Zhang C, Zhi H, Zhu J, Wang J, Liang Q, Hu Y, Li C. A phase II, randomized, controlled trial to evaluate the safety and immunogenicity of a Sabin strain-based inactivated polio vaccine. Hum Vaccin Immunother. 2020;16(11):2641–48. PMID: 32347778. doi:10.1080/21645515.2020.1745593.
   PubMedGoogle Scholar
• Hu Y, Wang J, Zeng G, Chu K, Jiang D, Zhu F, Ying Z, Chen L, Li C, Zhu F, et al. Immunogenicity and safety of a sabin strain-based inactivated polio vaccine: a phase 3 clinical trial. J Infect Dis. 2019;220(10):1551–57. PMID: 30958543. doi:10.1093/infdis/jiy736.
   PubMed Web of Science ®Google Scholar
• Chu K, Ying Z, Wang L, Hu Y, Xia J, Chen L, Wang J, Li C, Zhang Q, Gao Q, et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, dose-finding trial. Vaccine. 2018;36(45):6782–89. PMID: 30249424. doi:10.1016/j.vaccine.2018.09.023.
   PubMed Web of Science ®Google Scholar
• McNeil MM, Gee J, Weintraub ES, Belongia EA, Lee GM, Glanz JM, Nordin JD, Klein NP, Baxter R, Naleway AL, et al. The vaccine safety datalink: successes and challenges monitoring vaccine safety. Vaccine. 2014;32(42):5390–98. PMID: 25108215. doi:10.1016/j.vaccine.2014.07.073.
   PubMed Web of Science ®Google Scholar
• Fu S, Lin L, Cao F, Tian X, Chen T, Chen C, Huang B, Li D, Lv S, Zhou J. Comparison of immunization safety of 4 kinds of polio vaccines in Jilin province. Chin J Vaccines Immunization. 2017;23(4):379–82.
   Google Scholar
• Shi X, Zhou L, Zhou L, Liu L. Safety of domestic Sabin strain inactivated poliovirus vaccine. Chin J Vaccines Immunization. 2017;23(4):383–86.
   Google Scholar
• Wang S, Zhang C, Wang L, Zhao M. Suspected adverse events following immunization of poliomyelitis vaccines in Hubei province: analysis on surveillance data of 2015 – 2017. Chin J Public Health. 2018;34(5):736–40.
   Google Scholar
• China Ministry of Health, Food and Drug Administration of China. National guideline for the surveillance of adverse events following immunization. Beijing: China Ministry of Health, Food and Drug Administration of China; 2010 [accessed 2021 Jan 15]. http://www.nhc.gov.cn/jkj/zcwj2/new_zcwj_19.shtml.
   Google Scholar
• World Health Organization Regional Office for the Western Pacific. Immunization safety surveillance: guidelines for immunization programme managers on surveillance of adverse events following immunization [S]. 3rd ed. Manila (Philippines): World Health Organization; 2016 [accessed 2020 Oct 23]. https://www.who.int/publications/i/item/9789290617457.
   Google Scholar
• Klar S, Harris T, Wong K, Fediurek J, Deeks SL. Vaccine safety implications of Ontario, Canada’s switch from DTaP-IPV to Tdap-IPV for the pre-school booster. Vaccine. 2014;32(48):6360–63. PMID: 25252195. doi:10.1016/j.vaccine.2014.09.017.
   PubMed Web of Science ®Google Scholar
• Obando-Pacheco P, Rivero-Calle I, Gómez-Rial J, Rodríguez-Tenreiro Sánchez C, Martinón-Torres F. New perspectives for hexavalent vaccines. Vaccine. 2018;36(36):5485–94. PMID: 28676382. doi:10.1016/j.vaccine.2017.06.063.
   PubMed Web of Science ®Google Scholar
• Alguacil-Ramos AM, Muelas-Tirado J, Garrigues-Pelufo TM, Portero-Alonso A, Diez-Domingo J, Pastor-Villalba E, Lluch-Rodrigo JA. Surveillance for adverse events following immunization (AEFI) for 7 years using a computerized vaccination system. Public Health. 2016;135:66–74. PMID: 26976484. doi:10.1016/j.puhe.2015.11.010.
   PubMed Web of Science ®Google Scholar
• Patel PK, Al-Rawahi B, Al-Jawari A, Al-Abaidani I, Al-Abri S. Surveillance of adverse events following immunization in Oman, 2006–2015. East Mediterr Health J. 2018;24(2):119–26. [accessed 2020 Oct 23]. https://applications.emro.who.int/EMHJ/v24/02/EMHJ_2018_24_02_119_126.pdf.
   PubMed Web of Science ®Google Scholar
• Kim MK, Lee YK, Kim TE, Kong I, Yang HJ, Suh ES. Surveillance and compensation claims for adverse events following immunization from 2011 to 2016 in the Republic of Korea. Clin Exp Vaccine Res. 2017;6(2):146–55. PMID: 28775979. doi:10.7774/cevr.2017.6.2.146.
   PubMed Web of Science ®Google Scholar
• Li K, Ye J, Xu D, Wu W, Zhen J, Cao L, Cao L, Yuan P, Liu D, Wang H, et al. Surveillance of adverse events following immunization for inactivated poliovirus vaccine in China, in 2011–2013. Chin J Vaccines Immunization. 2015;21(2):139–46.
   Google Scholar
• Brotherton JM, Hull BP, Hayen A, Gidding HF, Burgess MA. Probability of coincident vaccination in the 24 or 48 hours preceding sudden infant death syndrome death in Australia. Pediatrics. 2005;115(6):e643–6. PMID: 15930190. doi:10.1542/peds.2004-2185.
   PubMed Web of Science ®Google Scholar
• Institute of Medicine (US) Immunization Safety Review Committee, Stratton K, Almario DA, Wizemann TM, McCormick MC, editors. Immunization safety review: vaccinations and sudden unexpected death in infancy. Washington (DC): National Academies Press (US); 2003. PMID: 25057654. doi: 10.17226/10649.
   Google Scholar
• Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the vaccine adverse event reporting system (VAERS). Vaccine. 2015;33(36):4398–405. PMID: 26209838. doi:10.1016/j.vaccine.2015.07.035.
   PubMed Web of Science ®Google Scholar
• Bonhoeffer J, Kohl K, Chen R, Duclos P, Heijbel H, Heininger U, Jefferson T, Loupi E. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine. 2002;21(3–4):298–302. PMID: 12450705. doi:10.1016/s0264-410x(02)00449-8.
   PubMed Web of Science ®Google Scholar